VA
Vivek Anand
The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Roswell Park Comprehensive Cancer Center
0000-0003-3793-1733
Employment
-
The University of Texas MD Anderson Cancer Center Instructor (Research Faculty)2025 - Present
-
The University of Texas MD Anderson Cancer Center Research fellow2020 - 2025
-
Memorial Sloan Kettering Cancer Center Research fellow2019 - 2020
-
Roswell Park Comprehensive Cancer Center Research affiliate2017 - 2019
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (29)
- Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer Save
- GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function Save
- GD3 Synthase is a Master Regulator of Wild-Type p53-Mediated Apoptosis and Mutant p53-Mediated Tumorigenesis Save
- GD3 synthase (ST8SIA1) is a key immunomodulator in GD2+breast cancer cells Save
- TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax Save
- Anti-B7-H3 Antibody (T-1A5) Blocks Immunomodulatory Function of B7-H3 and Enhances NK and T Cell-Mediated Cytotoxicity against Breast Cancer Cells Save
- Novel humanized anti-GD2 antibody inhibits GD2-mediated immunosuppression by targeting GD2+breast cancer stem-like cells Save
- Activin-like Kinase 2 (ALK2/ACVR1) Is a Resistance Factor and Therapeutic Vulnerability to FLT3 Inhibition in Acute Myeloid Leukemia Save
- Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer Save
- Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer Save